504538914
`
`09/08/2017
`
`PATENT ASSIGNMENT COVER SHEET
`
`Electronic Version v1.1
`Stylesheet Version v1.2
`
`EPASID: PAT4585621
`
`SUBMISSION TYPE: NEW ASSIGNMENT
`
`
`NATURE OF CONVEYANCE: ASSIGNMENT
`
`CONVEYING PARTY DATA
`
`Execution Date
`
`09/08/2017
`ALLERGAN, INC.
`
`
` 13655
`
`
`
`
`Total Attachments: 6
`
`RECEIVING PARTY DATA
`Name:
`SAINT REGIS MOHAWKTRIBE
`
`Street Address: 412 STATE ROUTE 37
`AKWESASNE
`City:
`NEW YORK
`State/Country:
`Postal Code:
`
`
`PROPERTY NUMBERS Total: 6
`Number
`Property Type
`
`Patent Number: 8629111
`
`Patent Number: 8633162
`
`Patent Number: 8642556
`
`Patent Number: 8648048
`
`Patent Number: 8685930
`Patent Number:
`9248191
`
`
`CORRESPONDENCE DATA
`Fax Number:
`
`(714)246-4249
`Correspondencewill be sent to the e-mail addressfirst; if that is unsuccessful, it will be sent
`using a fax number, if provided;if that is unsuccessful, it will be sent via US Mail.
`Phone:
`714-246-4500
`Email:
`
`Correspondent Name:
`AddressLine 1:
`AddressLine4:
`
`patents_ip@allergan.com
`ALLERGAN, INC.
`2525 DUPONTDRIVE, T2-7H
`IRVINE, CALIFORNIA 92612-1599
`
`ATTORNEY DOCKET NUMBER: 17618
`
`LAURAL. WINE
`NAME OF SUBMITTER:
`
`SIGNATURE: /Laura L. Wine/
`09/08/2017
`DATE SIGNED:
`
`504538914
`
`PATENT
`REEL: 043532 FRAME: 0422
`
`SRMT 2103 - Pg. 1
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`SRMT 2103 - Pg. 1
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`

`

`Signed#page6.tif
`
`source=Short form-Patent Assignment-
`source=Short form-Patent Assignment-
`source=Short form-Patent Assignment-
`source=Short form-Patent Assignment-
`source=Short form-Patent Assignment-
`source=Short form-Patent Assignment-
`
`Signed#page1 .tif
`Signed#page2.tif
`Signed#page3.tif
`Signed#pages.tif
`Signed#page5.tif
`
`PATENT
`REEL: 043532 FRAME: 0423
`
`SRMT2103 - Pg. 2
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`SRMT 2103 - Pg. 2
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`

`

`EXECUTION VERSION
`
`SHORT FORM PATENT ASSIGNMENT
`
`This Patent Assignment (this “Assignment’) is arate ag of September 8, 2017
`iguch date, the “Effective Date”), by and between Allergan, inc. a Delaware corporation
`C‘Assignar’}, and Saint Regis Mokhewk Tribe, a federally-recogmized sovervign Mative
`American Tribe Assignee"),
`
`WHEREAS, Assignar owns the paionty and patent applications set forth in
`Attachment A (the “Patents
`
`taunsfer, convey end deliver te
`WHEREAS, Assignor desires to assign,
`Assignee, and Aasignes wishes t0 acquire from Assignor, all ofits right, title and interest in, to
`and under the Patents; and
`
`WHEREAS, pursuant fo, and upon the term, abligations and conditions of, the
`Patent Assignment Agreement dated ag of September §, 2017 (the “Long Form Agreement”),
`byara] between Assignor and Assignes, Assignor desires to confine and perfect ifs aszignment,
`trunafer, conveyance and delivery to Assignee of all of its right, title and mtevest in, to and
`under the Patents end in, io and under the inventions represented thereby, and Assignee ig
`desirous of confirming and perfecting the same.
`
`the receipt and
`NOW, THEREFORE, for good and valuable consideration,
`sufficiensy of which are hereby acknowledged, the parties hensto, intending to be legally
`bound, hereby ggree ae follows:
`
`B
`fenment. As of the Effective TDste, Assignor hereby conveys, iansfirs, assigns
`ami
`delivers t Assignee, snd Assignee herchy accepts the from Assignor, all of
`Assignor’s ight, tile and Qiferest
`im, fo and under the Patents, together with any
`reissues, resxamination, divisions, continuations, comtinuations-in-part, extensions, and
`regewals of such Aasimred Patents already granted and which may be granted therean,
`The assignment contemplated hersin is meant io be an absolute assignment ancl not by
`way of seeurity,
`be vances. As may be necessary, Assignor shall execute, acknowledge and
`deliver such other ineumenis, decements ami agreaments and shell do euch other
`things aa may be reasonably necessary, proper or advisable to carry out Ne obligations
`under thig Agreement aad ag may be reasonably necessary, proper or advisable to more
`comipletely effeoniate, consunimiate,
`record, perfect or confirm the transactions
`contemptated hereby.
`
`3. BRecosdation The Assigner hereby autherizes the Director of Patents and Tradeimarks
`in the United States Patent and Trademark Office ts record Assignee as the assignee
`amd owner of the Assigned Patents and to deliver lo Assignes, amd ty Assigaee’s
`attorney, agents, gatsiessors or assigns, ol official documents amd communications as
`may be warranted by this Assignment, including but aot limited le issuing any and all
`Laters Patenta of the United States on inventions claimed in the Patents.
`
`
`4 NooXher Waivers of Sovercionbneamity. Agsignee represetiis that it has sew and will
`not waive is sovereign mmumonity or the aavereym immunity of any company,
`corporation, enterprise, authority, divinion, subdivision, branch of other agency,
`instrumentality or other goverment component of Assignee (aach of the foregoing,ps
`
`REEE*043532
`
` Oy BAT
`
`
`
`SRMT 2103 - Pg. 3
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`SRMT 2103 - Pg. 3
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`

`

`including Assignee, a “Tribst Party"), in each caxe, in relation fo aay inex partes
`reviewor any other proceeding in the United States Patent & Trademark Office or any
`ndminisirative proceeding that may be filed for the purpose of invalidating or rendering
`unenforceable any Assigned Patents. For purposes of this Assignment Agreement, no
`
`provision of this Assigament Agreement should be interpreted is consitute a waiver of
`Awignes’s or any other Tribal Party's sovereign immunity ae to any inter pertes review
`or spotlar proceedings.
`
`
`
`Greners]Provisions, Assignor and Assignes each acknowledge and agree that the
`represenintiins, warranties, covenants, obligations and other terms contained in the
`Long Form Agreement shall not be superseded hersby, Dut shall remain in fall force
`and effect te the full axtent provided therein. To the extent thet any provision of this
`Assignment ig inconsistent or conflicts with the Long Form Agreement, the provisions
`ofthe Long Form Agreement shall control. The parties may execute this Assignment
`inmuluple counterparts, any one of which sead got contain the signature ofmore then
`one party, but all such counterparts taken together shall constitute ons and the same
`instrament Any counterpart may be executed by faceimile or PDF signature end such
`facsimile or POP signature shell be deemed an original. The forms and conditions of
`this Assignment shall be binding upon the parties hereto and them mepiective successors
`and assigns. This Assignnient shall bs governed by and construed in accontance with
`the laws of the State of New York, without giving effect io the principles of conflicts
`ef law thereof,
`
`[Signatures Appear On The Following Page}
`
`Sue
`
` e/ BATENT —
`
`REEUWA3S37PRAME: 0425
`
`|
`
`SRMT2103 - Pg. 4
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`SRMT 2103 - Pg. 4
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`

`

`IN WITNESS THEREOF, Assignor and Assignes have caused their respective duly
`authorized officers to exucute this Assignment as af the Effective Date.
`
`Saint Regis Mohawk Tribe
`
`Allergan, ine.
`
`
`
`By:
`
`Name: Eric Thompson
`
`Name: A. Robert D Bailey
`
`Title: Presidsat
`
`Title: Pribal Chief
`
`
`
`Marne: Reverly Cook
`Title: Tribal Chief
`
`
`
`Name: Michael Conners
`
`Tithe: Tribal Claef
`
`Signanere Page to Short Form Pater?’ dasignnent Agreement
`
`
`
`¥ PATE
`REEL*=043532
`
`SRMT 2103 - Pg. 5
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`SRMT 2103 - Pg. 5
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`

`

`Alffechment A ~ The Patents
`
` Z FILINGDATE i
`
`
`Srarus/ Comments
`|
`
`
`
`17-May-1994 |
`20-Hon1998
`
`
`
` c“Nov2008 |: ior00s,829
`
` 3003
`
`
`
`“a.“Jan2018 "13/987,163
`
`
`
`~4967, 179
`14-Aug-2013
`
`“aeSao
`
`iL-Feb2014 |
`13/987,168
`—_
`|
`
`
`
`
`
`
`
`OL-ape20id 13/961,826| 07-Aug-2013
`[OLEFeb.2016 |
`14023478| 2DMar20ld |
`~ —
`
`
`
`
`
`. 1361835|OT-Aug2013 | Abandoned
`
`
`
`
`
`LMOSL BIS
`OF-Auge2O4 3
`Abandoned
`
`
`13/951 808
`Abandoned
`OF-Aug2013
`
`[31-Deo-2013 |
`11/897,177
`
`28-Aug-2007
`
`
`15/585,320 |3-May-2017oy
`“Pe
`
`
`
`
`
`
`
`15/011,159
`
`
`
`
`
`
`- 6503137|15-Sep-2003 | Lapsed Provisional
`
`
`
`|
`(927,857
`* Abandaned
`
`
`
`Abandoned
` "~_Abenuloned
`
`FARDSS
`
`TON, LSS
`“HATS,ae
`
`
`
`TEST 308
`
`|
`LSD448
`
`
`
`
`
`
`
`
`_UARB1409 i
`pSFaln
`
`f255,821
`|
`19-Ger-2008
`
`FIZ
`
`
`Adachmen A io Short Porm Peter dsvizament.Agreement
`
`ag
`A#weecE2 FRAME: 0427
`
`
`SRMT 2103 - Pg. 6
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`SRMT 2103 - Pg. 6
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`

`

`
`3.378,208
`
`
`
`
`LL8d0,652
`
`3-Mar-2018|
`
`LSATAa
`8,969,507
`
`13-Fab-200$
`
`228-F:007
`
`
` LoccfCea
`
`
`Abandoned
`
`_____Abatdoned
`
`
`Abandoned
`
`
`
`
`2-Aug2013
`_.
`Abandoned
`
`
`
`|
`SAVEIOLS
`|
`“Eka308Aton
`iar,796|
`
`
`13/997,B58|
`SAug2iy |
`_Peasling
`_“Abandoned
`
`
`
`
`Lapsed Provisional
`
`
`
`Lapsed Provisional
`i
`©E-Mar-2008
`
`
`|
`[202007
`
`
`(W858,200|26-Sep-2007
`
`
`22-Feb-200838 Abandoned
`
`Pending
`
`
`
`i
`
`AePATENT 0428
`
`SRMT2103- Pg. 7
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`SRMT 2103 - Pg. 7
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`

`

`Fane Gare |
`
`
`
`STATUS / COMMENTS
`_ Lapsed Provisional
`1 ~May-2009
`
`
`
`fay2018 |
` “25-May-2011
`
`
`
`
`
`
`27-Cee2014
`
`
`eet
` Abandoned
`
`
`Apo |
`
`
`
`
`
`2FebO16
`Pending
`
`
`e-Ang-2013
`.
`Abandoned
`
`
`
`
`Abandoned
`-Apr-201 4
`
`~BePeb-2016
`
`
`
`
`
`Aftiwhment 4 to Shore Form Patent AssignmentAgreement
`y
`
`“PATEN
`REEL: 043532 FRAME:
`
`RECORDED: 09/08/2017
`
`SRMT 2103 - Pg. 8
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`SRMT 2103 - Pg. 8
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01132
`
`